Jessica C Seidman1, Christian L Coles2, Ellen K Silbergeld2, Joshua Levens2, Harran Mkocha2, Lashaunda B Johnson2, Beatriz Muñoz2, Sheila K West2. 1. Department of International Health, Department of Environmental Health and Dana Center for Preventive Ophthalmology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, Kongwa Trachoma Project, Kongwa, United Republic of Tanzania and Biology Department, Morgan State University, Baltimore, MD, USA jseidman@jhsph.edu. 2. Department of International Health, Department of Environmental Health and Dana Center for Preventive Ophthalmology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, Kongwa Trachoma Project, Kongwa, United Republic of Tanzania and Biology Department, Morgan State University, Baltimore, MD, USA.
Abstract
BACKGROUND: Mass drug treatment with azithromycin (MDA) is part of the WHO-endorsed 'SAFE' strategy for trachoma control in endemic communities. MDA has been associated with reduced trachoma prevalence and short-term reductions in other bacterial infections, but can also lead to increased circulation of macrolide-resistant bacteria. METHODS: We prospectively monitored macrolide resistance in fecal E. coli collected from young children participating in the PRET+ Study in rural Tanzania. MDA was administered in four villages with >10% trachoma prevalence. Four nearby communities with lower trachoma prevalence served as controls. Rectal swabs were collected during cross-sectional surveys performed at baseline, 1, 3 and 6 months after MDA. Fecal E. coli isolates were screened for macrolide susceptibility using disc diffusion and minimum inhibitory concentration methods. Cross-sectional and longitudinal differences in resistance prevalence by MDA exposure were compared using t-tests and logistic regression. RESULTS: There was no difference in the proportion of individuals carrying azithromycin-resistant E. coli at baseline (0.21 vs. 0.16, P > 0.05). Azithromycin resistance carriage prevalence remained stable over follow-up in non-MDA villages but increased sharply in MDA villages (0.61 at 1 month, 0.42 at 3 months and 0.31 at 6 months). MDA exposure was highly associated with azithromycin resistance carriage at 1 month post-MDA (OR 15.27, P < 0.001) and subsequent surveys. Younger age and recent diarrhoea were also associated with increased odds of resistance (P < 0.01). CONCLUSIONS: MDA resulted in significantly increased prevalence of macrolide resistance in E. coli. Although MDA is effective for trachoma elimination, it has costs; it is essential to monitor antimicrobial resistance following MDA.
BACKGROUND: Mass drug treatment with azithromycin (MDA) is part of the WHO-endorsed 'SAFE' strategy for trachoma control in endemic communities. MDA has been associated with reduced trachoma prevalence and short-term reductions in other bacterial infections, but can also lead to increased circulation of macrolide-resistant bacteria. METHODS: We prospectively monitored macrolide resistance in fecal E. coli collected from young children participating in the PRET+ Study in rural Tanzania. MDA was administered in four villages with >10% trachoma prevalence. Four nearby communities with lower trachoma prevalence served as controls. Rectal swabs were collected during cross-sectional surveys performed at baseline, 1, 3 and 6 months after MDA. Fecal E. coli isolates were screened for macrolide susceptibility using disc diffusion and minimum inhibitory concentration methods. Cross-sectional and longitudinal differences in resistance prevalence by MDA exposure were compared using t-tests and logistic regression. RESULTS: There was no difference in the proportion of individuals carrying azithromycin-resistant E. coli at baseline (0.21 vs. 0.16, P > 0.05). Azithromycin resistance carriage prevalence remained stable over follow-up in non-MDA villages but increased sharply in MDA villages (0.61 at 1 month, 0.42 at 3 months and 0.31 at 6 months). MDA exposure was highly associated with azithromycin resistance carriage at 1 month post-MDA (OR 15.27, P < 0.001) and subsequent surveys. Younger age and recent diarrhoea were also associated with increased odds of resistance (P < 0.01). CONCLUSIONS: MDA resulted in significantly increased prevalence of macrolide resistance in E. coli. Although MDA is effective for trachoma elimination, it has costs; it is essential to monitor antimicrobial resistance following MDA.
Authors: Anthony W Solomon; Zeena Mohammed; Patrick A Massae; John F Shao; Allen Foster; David C W Mabey; Rosanna W Peeling Journal: Antimicrob Agents Chemother Date: 2005-11 Impact factor: 5.191
Authors: Paul M Emerson; Matthew Burton; Anthony W Solomon; Robin Bailey; David Mabey Journal: Bull World Health Organ Date: 2006-08 Impact factor: 9.408
Authors: Molly E Fleece; Rosemary Nshama; Thomas Walongo; Caroline Kimathi; Jean Gratz; Elizabeth T Rogawski McQuade; Jie Liu; Suporn Pholwat; Esto Mduma; Eric R Houpt; James A Platts-Mills Journal: Am J Trop Med Hyg Date: 2019-05 Impact factor: 2.345
Authors: Kieran S O'Brien; Sun Y Cotter; Abdou Amza; Boubacar Kadri; Beido Nassirou; Nicole E Stoller; Zhaoxia Zhou; Sheila K West; Robin L Bailey; Jeremy D Keenan; Travis C Porco; Thomas M Lietman Journal: Pediatr Infect Dis J Date: 2018-11 Impact factor: 2.129
Authors: Derick Ansah; Jerusha Weaver; Beatriz Munoz; Evan M Bloch; Christian L Coles; Thomas Lietman; Sheila K West Journal: Am J Trop Med Hyg Date: 2019-05 Impact factor: 2.345
Authors: Anthony W Solomon; Matthew J Burton; Emily W Gower; Emma M Harding-Esch; Catherine E Oldenburg; Hugh R Taylor; Lamine Traoré Journal: Nat Rev Dis Primers Date: 2022-05-26 Impact factor: 52.329
Authors: Evan M Bloch; Sheila K West; Kasubi Mabula; Jerusha Weaver; Zakayo Mrango; Beatriz Munoz; Thomas Lietman; Christian Coles Journal: Am J Trop Med Hyg Date: 2017-07-19 Impact factor: 2.345
Authors: Jennifer R Evans; Anthony W Solomon; Rahul Kumar; Ángela Perez; Balendra P Singh; Rajat Mohan Srivastava; Emma Harding-Esch Journal: Cochrane Database Syst Rev Date: 2019-09-26
Authors: Rebecca L Brander; Marcia R Weaver; Patricia B Pavlinac; Grace C John-Stewart; Stephen E Hawes; Judd L Walson Journal: Clin Infect Dis Date: 2020-01-06 Impact factor: 9.079